Motegrity contains prucalopride as its active component. Prucalopride is a selective serotonin 5-HT₄ receptor agonist used to improve bowel motility. In Hong Kong, Motegrity is a prescription-only medication regulated by the Department of Health under the Pharmacy and Poisons Ordinance. It is supplied as a 2 mg oral pill.
Prucalopride binds selectively to serotonin 5-HT₄ receptors located on the smooth muscle cells of the gastrointestinal (GI) tract. Activation of these receptors triggers a cascade that increases the release of acetylcholine, a neurotransmitter that stimulates muscle contractions. The result is:
Because prucalopride acts directly on the gut’s motor pathways, it works independently of the body's electrolyte balance or fluid intake. The drug reaches peak plasma concentrations within 2-3 hours after ingestion, and its effects on bowel movements are typically evident within a few days of regular use. Prucalopride is minimally metabolised and is excreted unchanged in the urine, giving it a relatively predictable pharmacokinetic profile.
Motegrity is approved in Hong Kong for the treatment of chronic constipation in adults who have not responded adequately to conventional laxatives. Chronic constipation is defined as fewer than three spontaneous bowel movements per week, accompanied by hard stools or a sensation of incomplete evacuation that persists for at least three months.
Typical candidates include:
Motegrity is not indicated for acute constipation, opioid-induced constipation, or bowel obstruction.
Current peer-reviewed studies have explored prucalopride for conditions such as irritable bowel syndrome with constipation (IBS-C) and neurogenic bowel dysfunction. However, these uses are not approved by the Hong Kong Department of Health. Off-label prescribing requires careful risk-benefit assessment and should be overseen by a qualified gastroenterologist.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
These effects are typically reported by more than 1 % of users and often resolve without medical intervention.
Note: Patients should inform their healthcare provider of all prescription medicines, over-the-counter drugs, supplements, and herbal products before starting Motegrity.
This article provides educational information about Motegrity and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Motegrity can be taken abroad, but you should carry the prescription label and a copy of the prescribing doctor's note. Some countries require documentation for import of prescription medicines, so verify local regulations before travel.
Motegrity 2 mg tablets are typically round, white, and bear the imprint “M2” on one side, indicating the brand and strength.
Prucalopride undergoes minimal hepatic metabolism, so mild liver impairment does not usually require dose adjustment. However, clinicians may still monitor liver function as a precaution.
Most patients notice an increase in stool frequency within 3 to 7 days of consistent daily dosing, though full therapeutic benefit may take up to two weeks.
Prucalopride is not a controlled substance and is not typically screened for in standard employment drug panels. It should not affect most workplace drug tests.
Yes, combining prucalopride with soluble fiber (e.g., psyllium) is generally safe and may enhance stool bulk, but increase fluid intake to avoid potential abdominal discomfort.
If nausea persists beyond the first week or is severe, contact your healthcare provider. They may suggest taking the pill with food or adjusting the dose.
Both contain the same active ingredient and share the same mechanism of action. Differences may lie in inactive excipients, which can affect tolerability for patients with specific allergies.
Routine blood tests are not required solely for prucalopride, but periodic renal function assessments are recommended, especially in patients with pre-existing kidney concerns.
Traditional laxatives primarily increase stool water content or stimulate intestinal irritation. Motegrity, as a prokinetic, directly enhances colonic motility, offering an alternative for patients who have not responded to laxatives alone.
